Medical School, Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, 69115, Germany.
Invest New Drugs. 2011 Jun;29(3):506-13. doi: 10.1007/s10637-009-9355-0. Epub 2009 Dec 9.
2´-Deoxy-5-fluorouridylyl-(5´-5´)-3´-C-ethynylcytidine [5-FdU(5´-5´)ECyd] and 3´-C-ethynylcytidinylyl-(5´->1-O)-2-O-octadecyl-sn-glycerylyl-(3-Ο->5´)-2´-deoxy-5-fluorouridine [ECyd-lipid-5-FdU] are antitumor active duplex drugs and these heterodinucleoside phosphate analogues could be cleaved in vivo by wide-spread phosphodiesterases into different antitumor active antimetabolites.
We cultured breast MCF-7, MDA-MB-231 and ovarian OVCAR-29 and OAW-42 cancer cell lines and used the luminometric measuring of the ATP tumor chemosensitivity assay to assess the in vitro activity of 5-FdU(5´-5´)ECyd and ECyd-lipid-5-FdU in comparison to standard single cytostatic agents and combinations thereof currently used in anticancer therapies. To allow comparison between samples and different regimens IndexSUM was determined based on the percentage tumor cell growth inhibition at each test drug concentration. Additionally, the cytostatic efficacy of 5-FdU(5´-5´)ECyd and ECyd-lipid-5-FdU was evaluated at a minimum of five concentrations at 10 fold dilutions using 60 human tumor cell lines including ovarian and breast cancer cell lines from the National Cancer Institute (USA).
5-FdU(5´-5´)ECyd and ECyd-lipid-5-FdU have a high cytostatic efficacy reaching 50% tumor cell growth inhibition at concentrations ranging between nano- and micomolar. IndexSum values for broad range efficacy in MCF-7 breast cancer cells were comparable to values obtained for standard drug combinations. Higher cytostatic efficacy was observed in MDA-MB-231 cells.
The duplex drugs 5-FdU(5´-5´)ECyd and ECyd-lipid-5-FdU represent potential new chemotherapeutic drugs for breast and ovarian cancer cells which are comparable to currently used drug combinations and more potent in comparison to some monocytostatica used in cancer therapy.
2´-脱氧-5-氟尿苷基-(5´-5´)-3´-C-乙炔基胞苷[5-FdU(5´-5´)ECyd]和 3´-C-乙炔基胞嘧啶基-(5´->1-O)-2-O-十八烷基-sn-甘油基-(3-Ο->5´)-2´-脱氧-5-氟尿苷[ECyd-脂质-5-FdU]是具有抗肿瘤活性的双链药物,这些杂核苷磷酸类似物可以在体内被广泛存在的磷酸二酯酶切割成不同的抗肿瘤活性代谢物。
我们培养乳腺癌 MCF-7、MDA-MB-231 和卵巢癌 OVCAR-29 和 OAW-42 癌细胞系,并使用发光测量的 ATP 肿瘤化学敏感性测定法来评估 5-FdU(5´-5´)ECyd 和 ECyd-脂质-5-FdU 的体外活性,与目前用于癌症治疗的标准单一细胞抑制剂及其组合进行比较。为了允许在不同方案之间进行比较,根据每个测试药物浓度下肿瘤细胞生长抑制的百分比确定 IndexSUM。此外,使用包括美国国立癌症研究所(USA)卵巢和乳腺癌细胞系在内的 60 个人类肿瘤细胞系,以 10 倍稀释度的至少五个浓度评估 5-FdU(5´-5´)ECyd 和 ECyd-脂质-5-FdU 的细胞抑制作用。
5-FdU(5´-5´)ECyd 和 ECyd-脂质-5-FdU 具有高细胞抑制作用,在纳摩尔和微摩尔范围内达到 50%的肿瘤细胞生长抑制。MCF-7 乳腺癌细胞中广谱疗效的 IndexSUM 值与获得的标准药物组合值相当。在 MDA-MB-231 细胞中观察到更高的细胞抑制作用。
双链药物 5-FdU(5´-5´)ECyd 和 ECyd-脂质-5-FdU 代表潜在的新型化疗药物,可用于乳腺癌和卵巢癌细胞,与目前使用的药物组合相当,并且比一些用于癌症治疗的单核细胞抑制剂更有效。